Mechanisms of Drug Resistance to Targeted Therapy in Malignancies

Articles

ORIGINAL RESEARCH

Published on 24 Jan 2024

IMiD/CELMoD-induced growth suppression of adult T-cell leukemia/lymphoma cells via cereblon through downregulation of target proteins and their downstream effectors

EDITORIAL

Published on 19 Jan 2024

Editorial: Mechanisms of drug resistance to targeted therapy in malignancies

ORIGINAL RESEARCH

Published on 03 Jan 2024

PLK1 and PARP positively correlate in Middle Eastern breast cancer and their combined inhibition overcomes PARP inhibitor resistance in triple negative breast cancer

ORIGINAL RESEARCH

Published on 08 Sep 2023

Synergism of the receptor tyrosine kinase Axl with ErbB receptors mediates resistance to regorafenib in hepatocellular carcinoma

ORIGINAL RESEARCH

Published on 21 Aug 2023

Low neutrophil-to-lymphocyte ratio predicts overall survival benefit in advanced NSCLC patients with low PD-L1 expression and receiving chemoimmunotherapy

ORIGINAL RESEARCH

Published on 19 Jun 2023

Tocilizumab (monoclonal anti-IL-6R antibody) reverses anlotinib resistance in osteosarcoma

Share on

Frontiers in Oncology

Submit your idea

Articles

IMiD/CELMoD-induced growth suppression of adult T-cell leukemia/lymphoma cells via cereblon through downregulation of target proteins and their downstream effectors

Editorial: Mechanisms of drug resistance to targeted therapy in malignancies

PLK1 and PARP positively correlate in Middle Eastern breast cancer and their combined inhibition overcomes PARP inhibitor resistance in triple negative breast cancer

Synergism of the receptor tyrosine kinase Axl with ErbB receptors mediates resistance to regorafenib in hepatocellular carcinoma

Low neutrophil-to-lymphocyte ratio predicts overall survival benefit in advanced NSCLC patients with low PD-L1 expression and receiving chemoimmunotherapy

Tocilizumab (monoclonal anti-IL-6R antibody) reverses anlotinib resistance in osteosarcoma

Frontiers in Oncology